LTGO (Latigo Biotherapeutics) Notes Receivable: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTGO Latigo Biotherapeutics Inc LTGO
8 GF Score
Price $18.05
View Full Analysis

What is Latigo Biotherapeutics Notes Receivable?

Latigo Biotherapeutics LTGO -1.10% 8 Notes Receivable is $0.00 Mil as of Dec. 2025. GuruFocus rates LTGO with a GF Score™ of 8/100.

Latigo Biotherapeutics's Notes Receivable for the quarter that ended in Dec. 2025 was $0.00 Mil.

Latigo Biotherapeutics Notes Receivable Related Terms

Latigo Biotherapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Latigo Biotherapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Latigo Biotherapeutics Notes Receivable Chart

Latigo Biotherapeutics Annual Data
Trend Dec24 Dec25
Notes Receivable
0.00 0.00

Latigo Biotherapeutics Semi-Annual Data
Dec24 Dec25
Notes Receivable 0.00 0.00
LTGO
8GF Score
Latigo Biotherapeutics Inc LTGO
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Latigo Biotherapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Latigo Biotherapeutics (LTGO) has a Notes Receivable of $0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Latigo Biotherapeutics and its competitors.
Is Latigo Biotherapeutics' Notes Receivable too high?
Latigo Biotherapeutics' current Notes Receivable is $0.00 Mil. Overall, Latigo Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Latigo Biotherapeutics' Notes Receivable compare to ?
Latigo Biotherapeutics' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Latigo Biotherapeutics and its competitors. Latigo Biotherapeutics's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Latigo Biotherapeutics stock overvalued right now?
Latigo Biotherapeutics (LTGO) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Latigo Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Latigo Biotherapeutics (LTGO), the current Notes Receivable is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Latigo Biotherapeutics Business Description

Comparable Companies
Address 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA, USA, 91320
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
8GF Score

Get the complete analysis for LTGO

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.05
Price